First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia

Abstract: In vivo expansion of haploidentical natural killer (NK) cell infusions with interleukin-2 (IL-2) can induce remission of refractory acute myeloid leukemia, but efficacy may be hampered by concurrent stimulation of host regulatory T cells. To overcome this limitation, we substituted the NK...

全面介紹

書目詳細資料

發表在:	Blood Advances
Main Authors:	Sarah Cooley, Fiona He, Veronika Bachanova, Gregory M. Vercellotti, Todd E. DeFor, Julie M. Curtsinger, Paul Robertson, Bartosz Grzywacz, Kevin C. Conlon, Thomas A. Waldmann, David H. McKenna, Bruce R. Blazar, Daniel J. Weisdorf, Jeffrey S. Miller
格式:	Article
語言:	英语
出版:	Elsevier 2019-07-01
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S2473952920306649